| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8487129 | PROGENICS PHARMS INC | Heterodimers of glutamic acid |
Nov, 2027
(3 years from now) | |
| US9861713 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(5 years from now) | |
| US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(6 years from now) | |
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(13 years from now) | |
Pylarify is owned by Progenics Pharms Inc.
Pylarify contains Piflufolastat F-18.
Pylarify has a total of 4 drug patents out of which 0 drug patents have expired.
Pylarify was authorised for market use on 26 May, 2021.
Pylarify is available in solution;intravenous dosage forms.
Pylarify can be used as method of positron emission tomography (pet) in men with prostate cancer.
Drug patent challenges can be filed against Pylarify from 26 May, 2025.
The generics of Pylarify are possible to be released after 09 June, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
Dosage: SOLUTION;INTRAVENOUS
PYLARIFY family patents
